The Sphingosine 1-Phosphate Receptor 1 pipeline drugs market research report outlays comprehensive information on the Sphingosine 1-Phosphate Receptor 1 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Sphingosine 1-Phosphate Receptor 1 pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
Smarter leaders trust GlobalData
The report also covers products from therapy areas such as Immunology, Central Nervous System, Gastrointestinal, and Dermatology which include the indications Rheumatoid Arthritis, Inflammation, Multiple Sclerosis, Neuropathic Pain (Neuralgia), Ulcerative Colitis, Crohn’s Disease (Regional Enteritis), Atopic Dermatitis (Atopic Eczema), and Alopecia Areata. It also reviews key players involved in Sphingosine 1-Phosphate Receptor 1 targeted therapeutics development with respective active and dormant or discontinued products.
The Sphingosine 1-Phosphate Receptor 1 pipeline targets constitutes close to 27 molecules. Out of which, approximately 26 molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, and Discovery stages are 1, 4, 8, 4, 8, and 1 respectively. Similarly, the universities portfolio in Preclinical comprises 1 molecule.
Sphingosine 1-Phosphate Receptor 1 overview
Sphingosine-1-phosphate receptor 1 (S1P receptor 1 or S1P1) is a G-protein coupled receptor. Signaling leads to the activation of RAC1, SRC, PTK2/FAK1 and MAP kinases. It plays an important role in cell migration, migration of osteoclast precursor cells, the regulation of bone mineralization and bone homeostasis and in the protection against ventilator-induced lung injury. It is required for normal chemotaxis toward sphingosine 1-phosphate, normal embryonic heart development and normal cardiac morphogenesis. It inhibits sprouting angiogenesis to prevent excessive sprouting during blood vessel development.
For a complete picture of Sphingosine 1-Phosphate Receptor 1’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.
Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
